Skip to content

Advertisement

  • Research
  • Open Access
  • Open Peer Review

Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 1,
  • 5,
  • 2 and
  • 2
Systematic Reviews20176:63

https://doi.org/10.1186/s13643-017-0445-3

©  The Author(s). 2017

  • Received: 9 September 2016
  • Accepted: 24 February 2017
  • Published:
Open Peer Review reports

Abstract

Background

A rigorous systematic review and meta-analysis focused on randomised controlled trials (RCTs) of non-individualised homeopathic treatment has not previously been reported. We tested the null hypothesis that the main outcome of treatment using a non-individualised (standardised) homeopathic medicine is indistinguishable from that of placebo. An additional aim was to quantify any condition-specific effects of non-individualised homeopathic treatment.

Methods

Literature search strategy, data extraction and statistical analysis all followed the methods described in a pre-published protocol. A trial comprised ‘reliable evidence’ if its risk of bias was low or it was unclear in one specified domain of assessment. ‘Effect size’ was reported as standardised mean difference (SMD), with arithmetic transformation for dichotomous data carried out as required; a negative SMD indicated an effect favouring homeopathy.

Results

Forty-eight different clinical conditions were represented in 75 eligible RCTs. Forty-nine trials were classed as ‘high risk of bias’ and 23 as ‘uncertain risk of bias’; the remaining three, clinically heterogeneous, trials displayed sufficiently low risk of bias to be designated reliable evidence. Fifty-four trials had extractable data: pooled SMD was –0.33 (95% confidence interval (CI) –0.44, –0.21), which was attenuated to –0.16 (95% CI –0.31, –0.02) after adjustment for publication bias. The three trials with reliable evidence yielded a non-significant pooled SMD: –0.18 (95% CI –0.46, 0.09). There was no single clinical condition for which meta-analysis included reliable evidence.

Conclusions

The quality of the body of evidence is low. A meta-analysis of all extractable data leads to rejection of our null hypothesis, but analysis of a small sub-group of reliable evidence does not support that rejection. Reliable evidence is lacking in condition-specific meta-analyses, precluding relevant conclusions. Better designed and more rigorous RCTs are needed in order to develop an evidence base that can decisively provide reliable effect estimates of non-individualised homeopathic treatment.

Keywords

  • Non-individualised homeopathy
  • Meta-analysis
  • Randomised controlled trials
  • Sensitivity analysis
  • Systematic review

Background

Homeopathy is a system of medicine based fundamentally on the ‘Principle of Similars’: a substance capable of causing symptoms of illness in a healthy subject can be used as a medicine to treat similar patterns of symptoms experienced by an individual who is ill; homeopathic medicines are believed to stimulate a self-regulatory healing response in the patient [1]. There are several distinct forms of homeopathy, the main types being ‘individualised homeopathy’, ‘clinical homeopathy’ and ‘isopathy’. In individualised homeopathy, typically a single homeopathic medicine is selected on the basis of the ‘total symptom picture’ of a patient, including his/her mental, general and constitutional type. In clinical homeopathy, one or more homeopathic medicines are administered for standard clinical situations or conventional diagnoses; where more than one medicine is used in a fixed preparation, it is referred to as a ‘combination’ (devised by researchers) or ‘complex’ homeopathic medicine (available as an over-the-counter [OTC] proprietary formulation). Isopathy is the use of homeopathic dilutions from the causative agent of the disease itself, or from a product of the disease process, to treat the condition [1]: isopathic medicines include organisms and allergens prescribed on a basis that is different from individualised homeopathic prescribing in the classical sense.

To inform appropriate research development in homeopathy, the nature of its existing research evidence needs to be examined with rigour, objectivity and transparency. In a previous systematic review of randomised controlled trials (RCTs) of individualised treatment, we concluded there was a small, statistically significant, effect of the individually prescribed homeopathic medicines that was robust to sensitivity analysis based on reliable evidence; however, the low or uncertain quality of the evidence prevented a decisive conclusion [2].

In contrast to individualised treatment, placebo-controlled RCTs of non-individualised homeopathic treatment evaluate interventions that have involved the same, standardised, medication allocated to each and every participant randomised to homeopathy in a given trial: single homeopathic medicine, combination or complex homeopathic medicine, or isopathy. In this RCT context, none of these approaches involves matching a patient with the ‘total symptom picture’ of an individually prescribed homeopathic medicine: a pre-selected medicine is applied to the typical symptoms of a clinical condition. In the analysis reported in the present paper, we therefore regard all trials of non-individualised homeopathic treatment as, in effect, testing the same intervention. A study protocol for this systematic review has been published [3].

Three of five prior comprehensive reviews of homeopathy RCTs, reflecting the broad spectrum of clinical conditions that has been researched, reached the guarded conclusion that the homeopathic intervention probably differs from placebo [4–6]. The fourth such review concluded, ‘The results of our meta-analysis are not compatible with the hypothesis that the clinical effects of homeopathy are completely due to placebo’ [7], though the same authors later published supplementary analysis that weakened this conclusion [8]. The fifth of these global systematic reviews concluded there was “weak evidence for a specific effect of homoeopathic remedies…compatible with the notion that the clinical effects of homoeopathy are placebo effects” [9]. In their approach, however, each of these ‘global’ reviews has assessed collectively the findings for individualised and non-individualised homeopathy, a method we regard as inappropriate due to the distinction between the two types of intervention in the RCT context. There have been two systematic reviews, with meta-analysis, of individualised homeopathy trials: the first was published in 1998 [10], the most recent in 2014 [2]. A focused meta-analysis of non-individualised homeopathy RCTs has not previously been reported.

In order to synthesise the findings from placebo-controlled RCTs of non-individualised homeopathy we conducted an up-to-date systematic review and meta-analysis, testing the following null hypothesis: across the entire range of clinical conditions that have been researched, the main outcome of treatment using a non-individualised homeopathic medicine cannot be distinguished from that using placebo. An additional aim, further informing future research, was to quantify any effect of non-individualised homeopathic treatment for each clinical condition for which there is more than a single eligible RCT.

Methods

Methods comply fully with the PRISMA 2009 Checklist (Additional file 1) and with our published protocol [3], which does not have a PROSPERO registration number.

Search strategy, data sources and trial eligibility

We conducted a systematic literature search to identify RCTs that compared non-individualised homeopathy with a placebo, for any clinical condition [11]. Each of the following electronic databases was searched from its inception up to the end of 2011, with updated searches of the same databases up to the end of 2014: AMED; CAM-Quest®; CINAHL; Cochrane Central Register of Controlled Trials; Embase; Hom-Inform; LILACS; PubMed; Science Citation Index and Scopus. For the update, CORE-Hom® was also searched, using the term ‘randomised’ or ‘unknown’ in the Sequence Generation field.

The full electronic search strategy for PubMed (Cochrane Highly Sensitive Search Strategy) is given in our previous paper [11]: “((homeopath* or homoeopath*) and ((randomized controlled trial [pt]) or (controlled clinical trial [pt]) or (randomized [tiab]) or (placebo [tiab]) or (clinical trials as topic [mesh:noexp]) or (randomly [tiab]) or (trial [ti]))) not (animals [mh] not humans [mh])”.

As stated in our published protocol [3], we then excluded trials: of crossover design; of radionically prepared homeopathic medicines; of homeopathic prophylaxis; of homeopathy combined with other (complementary or conventional) intervention; for other specified reasons. The final explicit exclusion criterion was that there was obviously no blinding of participants and practitioners to the assigned intervention; for example, a trial described by the original authors as ‘single [i.e. patient-] blinded’ was automatically excluded. All remaining trials were eligible for systematic review.

Outcome definitions

For each trial, and for the purposes of risk-of-bias assessment and meta-analysis, we identified a single ‘main outcome measure’ using a refinement of the approaches adopted by Linde et al. [7] and by Shang et al. [9]. Each trial’s ‘main outcome measure’ was identified based on the following hierarchical ranking order (consistent with the WHO International Classification of Functioning (ICF) linked to health condition [12]):

  • Mortality

  • Morbidity

    • ○ Treatment failure

    • ○ Pathology; symptoms of disease

  • Health impairment (loss/abnormality of function, incl. presence of pain)

  • Limitation of activity (disability, incl. days off work/school because of ill health)

  • Restriction of participation (quality of life)

  • Surrogate outcome (e.g. blood test data, bone mineral density).

We followed the WHO ICF system regardless of what measure may have been identified by the investigators as their ‘primary outcome’. In cases where, in the judgment of the reviewers, there were two or more outcome measures of equal greatest importance within the WHO ICF rank order, the designated ‘main outcome measure’ was selected randomly from those two or more options using the toss of coins or dice.

Unless otherwise indicated, the single end-point (measured from the start of the intervention) associated with the designated ‘main outcome measure’ was taken as the last follow-up at which data were reported for that outcome.

Data extraction

Two reviewers (RTM and either JC, JRTD, LL, SM, NR or C-MM) identified the main outcome measure and then independently extracted data for each trial using a standard recording approach [3]. The data extracted per trial included, as appropriate: demographics of participants (gender, age range, medical condition); study setting; potency or potencies of homeopathic medicines; whether a pilot trial; ‘main outcome measure’ (see above) and measured end-point; funding source/s. The statistical items noted were whether statistical power calculation carried out; whether intention-to-treat (ITT) analysis; sample size and missing data for each intervention group. Discrepancies in the interpretation of data were discussed and resolved by consensus.

Assessment of risk of bias

We used the domains of assessment as per the Cochrane risk-of-bias appraisal tool [13]. The extracted information enabled appraisal of freedom from risk of bias per domain: ‘Yes’ (low risk), ‘Unclear’ risk or ‘No’ (high risk). We applied this approach to each of the seven domains: sequence generation (domain I); allocation concealment used to implement the random sequence (II); blinding of participants and study personnel (IIIa); blinding of outcome assessors (IIIb); incomplete outcome data (IV); selective outcome reporting (V); other sources of bias (VI). The source of any research sponsorship (i.e. potential for vested interest) was taken into account for sub-group analysis (see below), but not in risk-of-bias assessment per se.

Reflecting appropriately the designated main outcome measure, we rated risk of bias for each trial across all seven domains and using the following classification [3]:

  • Rating A = Low risk of bias in all seven domains.

  • Rating Bx = Uncertain risk of bias in x domains; low risk of bias in all other domains.

  • Rating Cy.x = High risk of bias in y domains; uncertain risk of bias in x domains; low risk of bias in all other domains.

Designating an RCT as ‘reliable evidence’

An ‘A’-rated trial was designated reliable evidence. We also designated a ‘B1’-rated trial reliable evidence if the uncertainty in its risk of bias was for one of domains IV, V or VI only (i.e. it was required to be judged free of bias for each of domains I, II, IIIA and IIIB) [3]; in tabulations and text below, this rating is shown as ‘B1* (minimal risk of bias)’.

Study selection for meta-analysis

All RCTs that were included in the systematic review were potentially eligible for meta-analysis. If the original RCT paper did not provide adequate information on our selected main outcome measure to enable calculation of the SMD or the OR, we excluded the trial from the meta-analysis, and described the outcome as ‘not estimable’; consistent with Cochrane assessment criteria [13], such a trial was thus attributed high risk of bias in domain V.

Statistical analysis

Data preparation

For a continuous main outcome measure, the mean, standard deviation (SD) and number of subjects were extracted for homeopathy and placebo groups and the unbiased standardised mean difference (SMD) calculated, so that a negative SMD reflected a difference in favour of homeopathy. We did not adjust values to compensate for any inter-group differences at baseline. For a dichotomous main outcome measure, the number of subjects with a favourable outcome and the total number of subjects in each group were extracted to enable calculation of the odds ratio (OR), with values greater than 1 reflecting a difference in favour of homeopathy.

For a given trial comprising more than two study groups, only the data concerning comparisons between non-individualised homeopathy and placebo were extracted from the paper. For a trial in which there were two or more homeopathy groups, those groups’ data were combined in analysis where relevant and feasible: for a dichotomous measure, combining data merely required summing the events and sample sizes; for a continuous measure, combining data was feasible only where SD was derivable1.

For the pooled meta-analysis, a single measure of effect size was required to enable pooling of all relevant trials: ORs were transformed to SMD using a recognised approximation method [14]. This is a deviation from the protocol, which stated that SMD would be transformed to OR, as in a previous paper [2]. SMD and OR are equally valid statistics. The reasoning behind using SMD instead of OR is that the latter is intuitively associated with a dichotomous outcome, whereas the former has a direct connection with ‘effect size’ and indicates that, for the meta-analysis, it has been derived via transformation from other measures (including OR). Whichever of these two metrics is used, their results are interchangeable and their interpretation is identical. ‘Effect size’ was interpreted as follows: SMD <0.40 = ‘small’; SMD 0.40 to 0.70 = ‘moderate’; SMD >0.70 = ‘large’ [14]. Via the SMD-to-OR transformation factor above [14], these values correspond, respectively, to: OR <2.10 = ‘small’; OR 2.10 to 3.60 = ‘moderate’; OR >3.60 = ‘large’, which we used for our previous paper [2].

Heterogeneity and publication bias

Due to the known clinical heterogeneity between studies, random-effects meta-analysis regression models [15] were used to derive pooled estimators and for sub-group / moderator analyses. Estimates were derived along with their 95% confidence intervals (CI) and p values. The I 2 statistic was used to assess the variability between studies: it gives the percentage of the total variability in the estimated effect size (which is composed of between-study heterogeneity plus sampling variability) that is attributable to heterogeneity. The I 2 statistic can take values between 0 and 100%: I 2 = 0% means that all of the heterogeneity is due to sampling error, and I 2 = 100% means that all variability is due to true heterogeneity between studies.

Funnel plots and Egger’s test of asymmetry [16, 17] and the ‘trim-and-fill’ method [18, 19] were used to assess the impact of publication bias.

All statistical analyses were carried out in R version 3.1.2 and using the meta package [20].

Sensitivity analysis

The sensitivity analysis aimed to ascertain the impact of trials’ risk-of-bias rating on the pooled SMD: we examined the effect of cumulatively removing data from the meta-analysis by each trials’ rating, beginning with the lowest ranked ‘C’-rated trial/s.

Sub-group analysis

Included in sub-group analysis was whether a trial: (a) had been included or not in previous meta-analysis [9]; (b) was a ‘pilot’ study; (c) necessitated our use of imputed data for the meta-analysis; (d) was free of vested interest; (e) investigated either an ‘acute’ or a ‘chronic’ clinical condition.

As was implicit in the study protocol [3], and as presented in a previous paper [2], we also included the following in sub-group analysis: (f) whether a trial had sample size that was greater or less than the median for those included in meta-analysis; (g) whether a trial used homeopathic medicine/s with potency ≥12C or <12C (12-times serial dilution of 1:100 starting solution), a concentration sometimes regarded as equivalent to the ‘Avogadro limit’ for molecular dose [21]; potency was defined as ‘mixed’ if a combination medicine in a given trial comprised a mixture of ≥12C and <12C potencies.

As recognised by Cochrane, some issues suitable for such analysis are identified during the review process itself [22]. Thus, we additionally carried out sub-group analysis depending on whether (h) a trial had investigated a combination, an OTC complex, an isopathic or a single remedy.

Disease-specific treatment effect of non-individualised homeopathy

Analysis was carried out by clinical condition, in cases where there were ≥2 RCTs with extractable main outcome. Analysis was additionally carried out by category of clinical condition, including each category for which there were data from ≥2 RCTs. RCT nomenclature for clinical conditions and their categories was previously characterised [11]2.

All sub-group analyses were conducted before and after removal of ‘C’-rated trials [2].

Results

Included studies

The PRISMA flowchart from the original comprehensive literature search (up to and including 2011) was published previously [11]. An updated PRISMA flowchart is given in Fig. 1, identifying a total of 553 records.3 Four-hundred and fifty-four remained after removal of duplicates. After excluding 95 due to type of record (book chapter, thesis, abstract and other minor article), Three-hundred and fifty-nine full-text records were then assessed for eligibility. Two-hundred and eighty-seven were excluded for the general reasons summarised in Fig. 1; 38 of these same 287 were excluded from the present systematic review for the additionally specified reasons shown in Additional file 2.4 The finally remaining 72 records (75 RCTs) were thus included in this systematic review; data were not extractable from 21 of those, leaving 51 records (54 RCTs) available for meta-analysis—see Additional file 2 for details of the 21 records excluded from meta-analysis.
Fig. 1
Fig. 1

Updated PRISMA flowchart for all records published up to and including 2014

Characteristics of included studies

The 75 RCTs represent 48 different clinical conditions across 15 categories (Table 1). Each of 52 RCTs studied a condition that was acute in nature; each of 23 studied a chronic condition. Homeopathic potency was ≥12C in 29 trials, and not exclusively ≥12C for 7 trials (mix of >12C and <12C for 6 trials; unstated for 1 trial); potency was <12C in 39 trials. Seventeen trials were free of vested interest; 24 trials were not free of vested interest; 34 trials did not enable certainty in this assessment.
Table 1

Demographic data for 75 randomised controlled trials (RCTs) of non-individualised homeopathy: 21 excluded from meta-analysis shown by italics at first author's name

#

First author

Year

Category

Condition

Acute/ Chronic

Participants’ demographics

Study setting

Potency ≥12C

Hom. type

Funding source

Free of vested interest a

A42

Aabel

2001

Allergy and Asthma

Seasonal allergic rhinitis

Acute

Patients treated for hay fever due to birch pollen allergy

Specialist outpatient department in Norway

Y

Isopathy

Research Council of Norway. Homeopathic remedy and placebo tablets were gift from DCG, Gothenburg, Sweden

N

A43

Aabel

2000

Allergy and Asthma

Seasonal allergic rhinitis

Acute

Patients treated for hay fever due to birch pollen allergy

Specialist outpatient department in Norway

Y

Isopathy

Research Council of Norway. Homeopathic remedy and placebo tablets were gift from DCG, Gothenburg, Sweden

N

A44

Aabel

2000

Allergy and Asthma

Seasonal allergic rhinitis

Acute

Patients treated for hay fever due to birch pollen allergy

Specialist outpatient department in Norway

Y

Isopathy

Research Council of Norway. Homeopathic remedy and placebo tablets were gift from DCG, Gothenburg, Sweden

N

A47

Baker

2003

Mental Disorder

Anxiety

Acute

Anxious students, aged 18-60 years

University, Australia

N

Single

‘Brauer Biotherapies Pty Ltd (Adelaide) manufactured the homeopathic preparation specifically for the study’

U

A48

Balzarini

2000

Dermatology

Radiodermatitis

Acute

Patients with dermatitis caused by radiotherapy for breast cancer

Rehabilitation and palliative care department, Italy

Mixed

Combn.

None stated

U

A49

Beer

1999

Obstetrics and Gynaecology

Induction of labour

Acute

Women (at least 18 years old) between 38 and 42 weeks’ gestation and cervical dilation (≤3 cm)

Akademisches Lehrkrankenhaus der RWTH Aachen

N

Single

None stated

U

A50

Belon

2006

Toxicology

Arsenic toxicity

Chronic

People at high risk of arsenic contamination

Rural village, India

Y

Single

Hom pharm

N

A51

Belon

2007

Toxicology

Arsenic toxicity

Chronic

People at high risk of arsenic contamination

Rural village, India

Y

Single

Hom pharm

N

A52

Bergmann (a)

2000

Obstetrics and Gynaecology

Female infertility: oligomenorrhoea

Chronic

Women, age 18 - 40

Universitäts-Frauenklinik Heidelberg

N

OTC complex

None stated

U

A52

Bergmann (b)

2000

Obstetrics and Gynaecology

Female infertility: amenorrhoea

Chronic

Women, age 18 - 40

Universitäts-Frauenklinik Heidelberg

N

OTC complex

None stated

U

A53

Bernstein

2006

Dermatology

Psoriasis

Acute

Patients with psoriasis

Dermatology Centre in the USA

N

Single

“Supported in part” by Apollo Pharmaceuticals Inc., manufacturers of Reliéva

N

A55

Berrebi

2001

Obstetrics and Gynaecology

Postpartum lactation

Acute

Women immediately after childbirth and who did not wish to breast-feed

Childbirth unit, university hospital, Toulouse, France

N

Combn.

Hom pharm

N

A56

Bignamini

1987

Cardiovascular

Hypertension

Chronic

Elderly males or females with hypertension

Two old people’s homes, Italy

Y

Single

“We thank Laboratoires Boiron for material provided”

U

A59

Cialdella

2001

Mental Disorder

Withdrawal of benzodiazepines

Chronic

Men and women aged >18 years, taking BZD for >3 mo.

GP practices in France (multi-centre)

N

OTC complex b

External (hom pharm / govt.)

N

A60

Clark

2000

Musculoskeletal

Plantar fasciitis

Acute

Patients treated with heel pain due to fasciitis

Podiatry clinic, England

Y

Single

None stated

U

A272

Colau

2012

Obstetrics and Gynaecology

Menopausal syndrome

Chronic

Women aged ≥50 years; experienced amenorrhea for >12 months; spontaneously complained of hot flashes that had started <2 years previously

35 gynaecologist private practices in France

N

OTC complex

Hom pharm.

N

A61

Cornu

2010

Surgery and Anaesthesiology

Post-operative bleeding

Acute

Males or females, >18 years old, for whom elective aortic valve surgery planned

University hospital department, France

N

Combn.

Financially supported and assisted in design by Laboratoires Boiron, but ‘conducted in total independence’

U

A62

Diefenbach

1997

Respiratory Infection

Bronchitis

Acute

Patients (M/F) with bronchitis

4 doctors’ practices in Germany

N

OTC complex

None stated

U

A63

Ernst

1990

Cardiovascular

Varicose veins

Acute

Varicose veins in the legs

Rehabilitation clinic in Austria

N

OTC complex

None stated

U

A64

Ferley

1989

Respiratory Infection

Influenza

Acute

Age ≥12 years, flu-like symptoms, temp ≥38C

General practices in Rhône-Alpes region, France

Y

aIsopathy

None stated

U

A67

Frass

2005

Respiratory Infection

Tracheal secretions

Acute

Patients with accumulation of heavy secretions in the trachea

Intensive Care Unit at a university hospital in Austria

Y

Single

None stated

U

A68

Freitas

1995

Allergy and Asthma

Childhood asthma

Chronic

Children aged 12 mo to 12 years, with a mild to severe asthma crisis in the previous 6 mo.

Outpatient clinic in São Paulo, Brazil

N

Single

None stated

U

A69

Friese

2007

Ear, Nose and Throat

Sinusitis

Acute

Patients from 18 - 65 (m/f)

10 medical centres in Ukraine

N

OTC complex

None stated

U

A70

Friese

1997

Ear, Nose and Throat

Adenoid

Acute

Children (M/F) between age 4 and 10

Universitäts Kinderklinik Tübingen

Mixed

Combn.

Remedies were gift from hom pharm.

N

A74

Gerhard (a)

1998

Obstetrics and Gynaecology

Female infertility: amenorrhoea

Chronic

Women with secondary amenorrhoea

University hospital, Germany

N

OTC complex

Direct support from the company that provided the homeopathic medicine for the trial (senior author is company employee)

N

A74

Gerhard (b)

1998

Obstetrics and Gynaecology

Female infertility: luteal insufficiency

Chronic

Women with luteal insufficiency

University hospital, Germany

N

OTC complex

Direct support from the company that provided the homeopathic medicine for the trial (senior author is company employee)

N

A74

Gerhard (c)

1998

Obstetrics and Gynaecology

Female infertility: idiopathic

Chronic

Women with idiopathic infertility

University hospital, Germany

N

OTC complex

Direct support from the company that provided the homeopathic medicine for the trial (senior author is company employee)

N

A75

GRECHO

1989

Surgery and Anaesthesiology

Post-operative ileus

Acute

Men and women aged >18 years, having one of several stated operations

12 hospitals in France

Mixed

Combn.

Govt.

Y

A274

Harrison

2013

Mental Disorder

Insomnia

Chronic

Males aged 18-40, with chronic primary insomnia: at least 3 days per week for period of 1 mo to 10 years

University clinic

N

Combn.

University

Y

A76

Hart

1997

Surgery and Anaesthesiology

Post-operative pain

Acute

Patients with abdominal hysterectomy

Hospital, England

Y

Single

None stated

U

A78

Hitzenberger

2005

Cardiovascular

Hypertension

Chronic

Hypertensive patients (M/F)

Not explicitly mentioned

N

OTC complex

The study was funded, but it is not stated by whom

U

A79

Hofmeyr

1990

Obstetrics and Gynaecology

Postpartum pain

Acute

Postpartum women with episiotomy or perineal tearing requiring suture

University hospital, South Africa

N

Single b

None stated

U

A80

Jacobs

2006

Gastroenterology

Childhood diarrhoea

Acute

Children with a history of acute diarrhoea

Two municipal clinics, Honduras

Y

Combn.

External (hom research foundation)

Y

A81

Jacobs

2007

Tropical Disease

Dengue fever symptoms

Acute

Patients over age 12 with a case definition of dengue

Two health centres, Honduras

Y

Combn.

External (hom research foundation); meds ‘furnished’ by hom pharm

U

A83

Kaziro

1984

Surgery and Anaesthesiology

Post-operative pain/swelling

Acute

Patients with extraction of impacted wisdom teeth

Dental hospital, England

Y

Single

None stated

U

A84

Khuda-Bukhsh

2005

Toxicology

Arsenic toxicity

Chronic

People at high risk of arsenic contamination

Rural village, India

Y

Single

Hom pharm.

N

A85

Khuda-Bukhsh

2011

Toxicology

Arsenic toxicity

Chronic

People at high risk of arsenic contamination

Rural village, India

Y

Single

Hom pharm.

N

A86

Kim

2005

Allergy and Asthma

Seasonal allergic rhinitis

Acute

Asthmatic people allergic to house dust mite

College of Naturopathic Medicine and Health Sciences, USA

N

Isopathy

Internal / External (hom pharm)

N

A88

Kolia-Adam

2008

Mental Disorder

Insomnia

Chronic

Males or females, 18-50 years, suffering from insomnia for > 1 year

University health clinic, South Africa

Y

Single

None stated

U

A89

Kotlus

2010

Surgery and Anaesthesiology

Post-operative bruising

Acute

Males undergoing upper blepharoplasty

University department of ophthalmology, USA

Y

Combn.

Supported in part by external foundation

Y

A91

Labrecque

1992

Dermatology

Warts

Chronic

Aged 6-59 years and at least 1 plantar wart untreated during previous 3 months

Hospital-based family medicine unit, Canada

Mixed

Combn.

Hospital pharmacy

Y

A92

Leaman

1989

Dermatology

Minor burns

Acute

Aged 15-60 years with minor burns within previous 6 h

Hospital Accident and Emergency Dept, England

Y

Single

None stated

U

A93

Lewith

2002

Allergy and Asthma

Allergic asthma

Chronic

Asthmatic people allergic to house dust mite

Hospital clinic, England

Y

Isopathy

Internal / External (charity) / Purchase from hom pharm

Y

A94

Lipman

1999

Miscellaneous

Snoring

Acute

People treated for snoring

ENT specialist clinic in the USA

N

OTC complex

None stated

U

A293

Malapane

2014

Ear, Nose and Throat

Tonsillitis

Acute

Children, aged 6-12 years, with acute viral tonsillitis

University department of homeopathy, South Africa

N

OTC complex

None stated

U

A95

McCutcheon

1996

Mental Disorder

Anxiety

Acute

Adults with above average anxiety

University, USA

N

OTC complex

Hom pharm

N

A275

Naidoo

2013

Allergy and Asthma

Allergic skin reaction

Acute

Males or females, aged 18 to 45; positive skin test; living with a cat for a period of ≥ 6 mo; suffering from allergy-like symptoms

University health training centre

N

Combn.

None stated

U

A100

Oberbaum

2001

Oral/Dental

Stomatitis

Acute

Cancer patients with stomatitis

Children’s Medical Centre in Israel

N

OTC complex

None stated

U

A101

Oberbaum

2005

Obstetrics and Gynaecology

Postpartum bleeding

Acute

Women after childbirth

Medical centre in Israel

Mixed

Combn.

Research foundation

Y

A103

Padilha

2011

Toxicology

Lead poisoning

Acute

Workers at risk of lead contamination

Clinic of battery plant, Brazil

Y

Single

Explicitly no funding source

Y

A104

Papp

1998

Respiratory Infection

Influenza

Acute

Age 12-60 years, specified flu-like symptoms, onset within last 24 h, temp ≥38C

General or specialist medical practices, Germany

Y

a Isopathy

None stated

U

A105

Paris

2008

Surgery and Anaesthesiology

Post-operative analgesic intake

Acute

Male or female, aged 18-60 years, undergoing surgery of anterior cruciate ligamen

University hospital, France

N

Combn.

Hom pharm

N

A108

Rahlfs

1976

Gastroenterology

Irritable bowel syndrome

Acute

Patients, male or female, aged 20-60, with diagnosis of irritable bowel syndrome

12 general medical practices in Germany

N

Single b

None stated

U

A109

Rahlfs

1978

Gastroenterology

Irritable bowel syndrome

Acute

Patients, male or female, aged 20-60, with diagnosis of irritable bowel syndrome

39 general medical practices in Germany

N

Single

External (hom research foundation)

Y

A277

Razlog

2012

Mental Disorder

ADHD

Chronic

School children, aged 5-11, diagnosed with ADHD

Primary schools in South Africa

N

Single

University

Y

A111

Reilly

1986

Allergy and Asthma

Seasonal allergic rhinitis

Acute

Patients aged over 5 with at least a 2-year history of seasonal rhinitis and current symptoms of grass pollen allergy

Two hospital clinics and 26 NHS general practitioners in the UK

Y

Isopathy

External: charity; govt.

Y

A112

Reilly

1994

Allergy and Asthma

Allergic asthma

Chronic

Patients aged over 16 with at least a 1-year history of asthma and reactive to inhaled allergens

Asthma outpatient clinic, Scotland

Y

Isopathy

External / purchase from hom pharm

Y

A113

Robertson

2007

Surgery and Anaesthesiology

Post-operative pain

Acute

Patients over the age of 18 undergoing tonsillectomy

Hospital, England

Y

Single

Internal / External (hom pharm)

N

A116

Schmidt

2002

Miscellaneous

Those benefited by reduced body weight

Acute

Fasting patients encountering static or increased body weight

Hospital for internal and complementary medicine, Germany

Y

Single

“The foundation of the Krankenhaus für Naturheilweisen funded the study, paying salaries or fees to contributors and collaborators.”

U

A117

Seeley

2006

Surgery and Anaesthesiology

Post-operative bruising

Acute

Female patients undergoing elective rhytidectomy

Hospital, Canada

Unknown

Single

Hom pharm.

N

A278

Sencer

2012

Oral/Dental

Mucositis

Acute

Patients aged 3-25 years, undergoing myeloablative haematopoietic SCT for malignant and non-malignant conditions

Oncology centres in USA, Canada and Israel

N

OTC complex

Government (NIH) grant

Y

A120

Singer

2010

Surgery and Anaesthesiology

Post-operative pain

Acute

Patients (M/F) age > = 18

2 centres

N

OTC complex

Financial support by producing company which ‘supplied the study medication’ but, by contractual agreement, had ‘no control over the flow of the study, the data analysis, or the decision when and where to publish the study findings’

Y

A122

Stevinson

2003

Surgery and Anaesthesiology

Post-operative pain/swelling

Acute

Aged 18–70 years undergoing elective hand surgery for carpal tunnel syndrome

Hospital, England

Y / N

Single b

Hom. research foundation / drugs ‘supplied by’ hom pharm

U

A123

Taylor

2000

Allergy and Asthma

Perennial allergic rhinitis

Chronic

Patients with allergy to house dust mites, animals, pollens or foods

Specialist outpatient department in the UK

Y

Isopathy

External (hom and non-hom charities)

Y

A125

Tveiten

1991

Musculoskeletal

Muscle soreness

Acute

Male marathon runners, Norway

City of Oslo

Y

Single

None stated

U

A126

Tveiten

1998

Musculoskeletal

Muscle soreness

Acute

Marathon runners, Norway

City of Oslo

Y

Single

Research Council of Norway. Homeopathic remedy and placebo tablets were gift from hom pharm.

N

A128

Vickers

1998

Musculoskeletal

Muscle soreness

Acute

Long-distance runners, aged 18 or over, England

London community

Y

Single

Charity / drugs gifted by hom pharm

N

A130

Weiser

1994

Ear, Nose and Throat

Sinusitis

Chronic

Patients (M/F) with chronic sinusitis

11 ENT doctors’ practices in Germany

N

OTC complex b

None stated

U

A131

Wiesenauer

1985

Allergy and Asthma

Seasonal allergic rhinitis

Acute

Patients treated for hay fever

Doctors’ practices in Germany

N

Single

External (hom pharm)

N

A132

Wiesenauer

1989

Ear, Nose and Throat

Sinusitis

Acute

Patients (M/F) with acute or chronic sinusitis

47 doctors’ practices

N

Combn. c

Funded by two foundations

Y

A133

Wiesenauer

1990

Allergy and Asthma

Seasonal allergic rhinitis

Acute

M/F, all ages

54 doctors’ practices

N

Single

Funded by two foundations

Y

A134

Wiesenauer

1991

Rheumatology

Rheumatoid arthritis

Chronic

Patients (m/f), age 18 - 70, with chronic polyarthritis

6 doctors’ practices

N

OTC complex

None stated

U

A135

Wiesenauer

1995

Allergy and Asthma

Seasonal allergic rhinitis

Acute

Patients treated for hay fever

Doctors’ practices in Germany

N

Single

None stated

U

A136

Wolf

2003

Surgery and Anaesthesiology

Post-operative pain

Acute

Age 10 - 65 (M/F), varicose veins

Gefäßchirurgische Klinik in Berlin-Buch

N

Single

Remedies were gift from hom pharm.

N

A137

Zabolotnyi

2007

Ear, Nose and Throat

Sinusitis

Acute

Patients, aged 18-60 years, treated for acute maxillary sinusitis, with at least 8 d of symptoms

ENT specialist clinics, Ukraine

N

OTC complex

None stated

U

Y yes, U unclear, N no, Combn. combination, M/F male/female

aVested interest: support (direct, through research sponsorship; indirect, via gifted medicines) from company that provided homeopathic medicines for the trial

bSingle RCT comprising two homeopathy groups

cSingle RCT comprising three homeopathy groups

Summary of findings

For each trial, Table 2 includes details of the sample size, the identified main outcome measure (and whether dichotomous or continuous) and the study end-point. Seventeen trials were described in the original paper as a ‘pilot’ (or ‘preliminary’ or ‘feasibility’) study. A power calculation was carried out for 28 of the trials. ITT was the basis for analysis in 21 trials. Mean attrition rate was 14.6%. The main outcome variable was dichotomous in 25 studies and continuous in the other 50. The total sample size for the 54 meta-analysable trials was 5032; the median sample size was 62.5 (inter-quartile range, 36 to 107). Meta-analysable studies included 45 different main outcome measures and for an end-point that ranged from 6 h to 6 months. Table 2 also indicates the 25 analysed trials in our study that we have in common with those included in the meta-analysis data reported by Shang et al. [9].
Table 2

Summary of findings table: 21 excluded from meta-analysis shown by italics at first author's name

#

First author

Year

Pilot

Power calc.

ITT sample

PP sample

PP sample > median (62.5)

Attrition rate %

Original ITT analysis

‘Main’ outcome identified

Nature of ‘main’ outcome

End-point

A42

Aabel

2001

N

N

51

51

N

0.0

N

Daily symptom score (VAS)

Continuous

10 days

A43

Aabel

2000

N

Y

70

66

Y

5.7

N

Daily symptom score

Continuous

32 days

A44

Aabel

2000

N

Y

80

73

Y

8.8

N

Daily symptom score (VAS)

Continuous

10 days

A47

Baker

2003

N

Y

?

44

N

?

N

Revised Test Anxiety (RTA) scale

Continuous

4 days

A48

bBalzarini

2000

N

N

66

61

N

7.6

N

Index of Total Severity during Recovery (re: skin colour, temp, oedema, pigmentation)

Continuous

7–8 weeks

A49

bBeer

1999

N

N

40

40

N

0.0

Y

Time between to regular uterine contractions

Continuous

7 h or induction of labour

A50

Belon

2006

N

N

43

43

N

0.0

N

Reversal in expression of antinuclear antibody titre

Dichotomous

1 month

A51

Belon

2007

Y

N

39

25

N

35.9

N

Blood arsenic concentration

Continuous

2 months

A52

bBergmann (a)

2000

N

Y

?

37

N

?

N

Cycle normalisation

Dichotomous

3 months or 3 cycles

A52

bBergmann (b)

2000

N

Y

?

30

N

?

Y

Cycle normalisation

Dichotomous

3 months or 3 cycles

A53

Bernstein

2006

N

N

200

171

Y

14.5

N

Psoriasis Area Severity Index

Continuous

12 weeks

A55

Berrebi

2001

N

N

71

71

Y

0.0

N

Mammary pain (VAS)

Continuous

4 days

A56

Bignamini

1987

N

N

34

32

N

5.9

N

(Systolic) Blood pressure

Continuous

4 weeks

A59

bCialdella

2001

N

Y

96

61

N

36.5

Y

“Success rate” for clinical global impression

Dichotomous

30 days

A60

Clark

2000

Y

N

18

14

N

22.2

N

Daily pain (100 mm VAS)

Continuous

14 days

A272

Colau

2012

N

Y

108

101

Y

6.5

Y

Hot flash score

Continuous

12 weeks

A61

Cornu

2010

Y

Y

92

92

Y

0.0

Y

Cumulated blood loss at drain removal

Continuous

Up to 7 d

A62

bDiefenbach

1997

N

N

258

209

Y

19.0

Y

Treatment success (‘very good’ + ‘good’ results) – physician-assessed

Dichotomous

Up to 3 weeks

A63

bErnst

1990

N

N

122 a

122 a

N

0.0

N

Venous filling time

Continuous

24 days

A64

bFerley

1989

N

N

478

462

Y

3.3

N

Proportion of patients recovered (from 5 cardinal symptoms and from temp > 37.5)

Dichotomous

By 48 h

A67

Frass

2005

N

N

55

50

N

9.1

N

Total volume of tracheal secretions per day

Continuous

2 days

A68

bFreitas

1995

N

N

86

69

Y

19.8

N

Score of intensity, frequency and duration of symptoms

Continuous

6 months

A69

Friese

2007

N

N

144

68

Y

52.8

Y

Sinusitis symptoms score

Continuous

21 days

A70

bFriese

1997

N

Y

97

82

Y

15.5

N

Frequency of non-adenoidectomy (imputed)

Dichotomous

3 months

A74

Gerhard (a)

1998

N

Y

38

28

N

26.3

N

Frequency of pregnancy

Dichotomous

3 months

A74

Gerhard (b)

1998

N

Y

27

21

N

22.2

N

Frequency of pregnancy

Dichotomous

3 months

A74

Gerhard (c)

1998

N

Y

31

17

N

45.2

N

Frequency of pregnancy

Dichotomous

3 months

A75

GRECHO

1989

N

Y

300

300

Y

0.0

N

Number of hours from operation until first stool

Continuous

Up to c.100 h

A274

Harrison

2013

Y

N

34

28

N

17.6

N

Sleep onset latency

Continuous

28 days

A76

Hart

1997

N

N

93

73

Y

21.5

N

Frequency of improved pain score (VAS)

Dichotomous

Duration of 5 days

A78

Hitzenberger

2005

N

Y

?

?

-

?

N

Blood pressure

Continuous

6 weeks

A79

bHofmeyr

1990

Y

N

162

161

Y

0.6

N

Daily questionnaire responses: those without moderate/severe perineal pain

Dichotomous

4 days

A80

Jacobs

2006

N

N

292

265

Y

9.2

Y

Duration of diarrhoea

Continuous

Up to 7 days

A81

Jacobs

2007

Y

N

60

58

N

1.7

N

No. of days until no pain or fever for at least two consecutive days

Continuous

Up to 1 weeks

A83

bKaziro

1984

N

N

77

77

Y

0.0

N

Pain score (VAS): Numbers without moderate/severe pain (imputed)

Dichotomous

8 days

A84

Khuda-Bukhsh

2005

Y

N

55

55

N

0.0

N

Urine arsenic concentration (imputed)

Continuous

11 days

A85

Khuda-Bukhsh

2011

Y

N

28

14

N

50.0

N

Urine arsenic concentration

Continuous

2 months

A86

Kim

2005

Y

Y

40

34

N

15.0

Y

Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ total symptoms)

Continuous

4 weeks

A88

Kolia-Adam

2008

N

N

30

30

N

0.0

N

Hours of sleep per night

Continuous

8 weeks

A89

Kotlus

2010

N

N

60

57

N

5.0

N

Area of ecchymosis

Continuous

7 days

A91

Labrecque

1992

N

Y

174

162

Y

6.9

N

Proportion of pts with healed warts (physician assessment)

Dichotomous

18 weeks

A92

bLeaman

1989

N

N

34

34

N

0.0

N

Pain (0-10 VAS) - area-under-the-curve

Continuous

6 h

A93

Lewith

2002

N

N

242

202

Y

16.5

Y

Asthma VAS (imputed)

Continuous

16 weeks

A94

Lipman

1999

N

N

101

90

Y

10.9

N

Average snoring score computed from responses to Snore Diary over last 5 nights of 10

Continuous

Duration of 10 days

A293

Malapane

2014

Y

N

30

30

N

0.0

N

Tonsillitis pain score (Wong-Baker FACES)

Continuous

6 days

A95

McCutcheon

1996

N

N

77

58

N

24.7

N

State Anxiety score

Continuous

Duration of 15 days

A275

Naidoo

2013

Y

N

30

30

N

0.0

N

Wheal diameter

Continuous

4 weeks

A100

Oberbaum

2001

N

N

32

30

N

6.3

Y

Area-under-the-curve score for stomatitis symptoms (severity and duration) (imputed)

Continuous

14 days minimum

A101

bOberbaum

2005

Y

N

45

40

N

11.1

Y

Venous haemoglobin

Continuous

72 h postpartum

A103

Padilha

2011

N

N

131

120

Y

8.4

Y

Proportion of workers with Pb decrease of at least 25% (imputed)

Dichotomous

30 days

A104

bPapp

1998

N

N

372

334

Y

10.2

N

Proportion of patients with physician-assessed recovery in health (i.e. ‘no symptoms’)

Dichotomous

By 48 h

A105

Paris

2008

N

Y

131

105

Y

19.8

Y

Proportion patients with cumulated consumption of morphine < 10 mg/day (imputed)

Dichotomous

24 h post-op

A108

bRahlfs

1976

Y

Y

?

63

Y

?

N

Improvement of irritable bowel syndrome (scale 1 + 2)

Dichotomous

14 days

A109

bRahlfs

1978

Y

N

119

85

Y

28.6

N

Improvement of irritable bowel syndrome (scale 3 + 4)

Dichotomous

15 days

A277

Razlog

2012

Y

N

20

18

N

10.0

N

Conner’s PSQ (‘Impulsivity and/or hyperactivity’ category)

Continuous

3 weeks

A111

bReilly

1986

N

Y

158

109

Y

31.6

N

Propn. with improvement in daily overall VAS score (imputed)

Dichotomous

5 weeks

A112

bReilly

1994

N

Y

28

24

N

14.3

Y

Propn. with improvement in daily overall VAS score

Dichotomous

4 weeks

A113

Robertson

2007

N

Y

190

111

Y

41.6

N

Tonsillectomy pain (VAS) score

Continuous

14 days

A116

Schmidt

2002

N

Y

208

194

Y

6.7

Y

Reduction of body weight

Continuous

3 days

A117

Seeley

2006

N

N

29

26

N

10.3

N

Area of ecchymosis

Continuous

10 days

A278

Sencer

2012

N

Y

195

106

Y

45.6

N

Sum of Walsh scores for mucositis

Continuous

Up to 20 days post-transplant

A120

Singer

2010

N

Y

80

79

Y

1.3

Y

Area-under-the-curve pain score

Continuous

14 days

A122

Stevinson

2003

Y

N

64

62

N

3.1

Y

Pain (Short Form McGill Pain Questionnaire

Continuous

14 days

A123

bTaylor

2000

N

Y

51

50

N

2.0

Y

Daily overall VAS score (imputed)

Continuous

3–4 weeks

A125

Tveiten

1991

N

N

44

36

N

18.2

N

Muscle soreness (VAS) (imputed)

Continuous

3 days

A126

bTveiten

1998

N

N

?

46

N

?

N

Muscle soreness (VAS)

Continuous

3 days

A128

bVickers

1998

N

Y

?

400

Y

?

Y

Muscle soreness (VAS)

Continuous

2 days

A130

Weiser

1994

N

Y

173

155

Y

10.4

N

Sinusitis score

Continuous

5 months or on relapse

A131

bWiesenauer

1985

N

N

106

74

Y

30.2

N

Symptom relief (nasal): ‘Symptom-free’ + ‘Obvious relief’

Dichotomous

4 weeks

A132

Wiesenauer

1989

N

N

221

152

Y

31.2

N

Sinusitis score

Continuous

3–4 weeks

A133

bWiesenauer

1990

N

N

243

171

Y

29.6

N

Symptom relief (nasal): ‘Symptom-free’ + ‘Obvious relief’

Dichotomous

Approx 5 weeks

A134

Wiesenauer

1991

N

N

176

106

Y

39.8

N

Treatment success

Dichotomous

12 weeks

A135

bWiesenauer

1995

N

N

132

120

Y

9.1

N

Symptom relief (nasal): ‘Symptom-free’ + ‘Obvious relief’

Dichotomous

4 weeks

A136

Wolf

2003

Y

N

60

59

N

1.7

N

Haematoma area

Continuous

2 weeks

A137

Zabolotnyi

2007

N

Y

113

113

Y

5.3

Y

Sinusitis severity score cf. Day 0 (imputed)

Continuous

7 days

ITT intention to treat, PP per protocol, Y yes, N no

aSample size refers to number of legs, not the number of subjects, in the trial

bIncluded in meta-analysis by Shang et al. [http://www.ispm.unibe.ch/unibe/portal/fak_medizin/ber_vkhum/inst_smp/content/e93945/e93964/e180045/e180897/1433.Study_characteristics_of_homoeopathy_studies_corrected_eng.pdf (accessed 1 July 2016)]

Risk of bias and reliable evidence

Table 3 provides the risk-of-bias details for each of the 75 trials, and sub-divided by: (a) the 54 that could be included in meta-analysis; (b) the 21 that could not be included in meta-analysis. Domains IV (completeness of outcome data), V (selective outcome reporting) and VI (other sources of bias) presented the greatest methodological concerns. Sixteen of 30 trials that were high risk of bias for domain V were so because their data were not extractable for meta-analysis (see Study selection for meta-analysis above). Domain II (allocation concealment) presented the most uncertain methodological judgments, with 55 (73%) trials assessed unclear risk of bias and only 14 (19%) low risk of bias.
Table 3

Risk-of-bias assessments for trials: (a) included in meta-analysis; (b) not included in meta-analysis

   

Risk-of-bias domain

  

#

First author

Year

I

II

IIIa

IIIb

IV

V c

VI

Risk of bias

Risk-of-bias rating

(a) Included in meta-analysis

A272

Colau

2012

Y

Y

Y

Y

Y

Y

Y

Low a

A

A103

Padilha

2011

Y

Y

Y

Y

Y

Y

Y

Low a

A

A120

Singer

2010

Y

Y

Y

Y

Y

Y

U

Uncertain a

B1*

A123

Taylor

2000

Y

U

Y

Y

Y

Y

Y

Uncertain

B1

A47

Baker

2003

Y

Y

Y

Y

U

Y

U

Uncertain

B2

A61

Cornu

2010

Y

Y

U

U

Y

Y

Y

Uncertain

B2

A67

Frass

2005

U

U

Y

Y

Y

Y

Y

Uncertain

B2

A93

Lewith

2002

U

U

Y

Y

Y

Y

Y

Uncertain

B2

A275

Naidoo

2013

U

U

Y

Y

Y

Y

Y

Uncertain

B2

A105

Paris

2008

U

Y

Y

Y

U

Y

Y

Uncertain

B2

A126

Tveiten

1998

Y

U

Y

Y

U

Y

Y

Uncertain

B2

A128

Vickers

1998

Y

Y

Y

Y

U

Y

U

Uncertain

B2

A137

Zabolotnyi

2007

Y

U

Y

Y

Y

U

Y

Uncertain

B2

A100

Oberbaum

2001

U

U

Y

Y

Y

Y

U

Uncertain

B3

A62

Diefenbach

1997

U

U

Y

U

U

Y

Y

Uncertain

B4

A64

Ferley

1989

U

U

Y

U

Y

U

Y

Uncertain

B4

A79

Hofmeyr

1990

Y

U

U

U

Y

U

Y

Uncertain

B4

A92

Leaman

1989

U

U

Y

Y

U

Y

U

Uncertain

B4

A293

Malapane

2014

U

U

U

U

Y

Y

Y

Uncertain

B4

A125

Tveiten

1991

U

U

Y

U

U

Y

Y

Uncertain

B4

A135

Wiesenauer

1995

U

U

Y

Y

U

Y

U

Uncertain

B4

A112

Reilly

1994

U

U

U

U

Y

Y

U

Uncertain

B5

A48

Balzarini

2000

U

U

U

U

U

Y

U

Uncertain

B6

A75

GRECHO

1989

U

U

U

U

U

Y

U

Uncertain

B6

A83

Kaziro

1984

U

U

U

U

U

Y

U

Uncertain

B6

A104

Papp

1998

U

U

Y

U

U

U

U

Uncertain

B6

A81

Jacobs

2007

Y

Y

Y

Y

Y

Y

N

High

C1.0

A131

Wiesenauer

1985

Y

U

Y

Y

N

Y

Y

High

C1.1

A68

Freitas

1995

Y

U

Y

Y

N

Y

U

High

C1.2

A111

Reilly

1986

U

U

Y

Y

N

Y

Y

High

C1.2

A113

Robertson

2007

Y

U

Y

Y

N

Y

U

High

C1.2

A133

Wiesenauer

1990

U

U

Y

Y

N

Y

Y

High

C1.2

A86

Kim

2005

Y

U

U

U

N

Y

Y

High

C1.3

A134

Wiesenauer

1991

U

U

Y

U

N

Y

Y

High

C1.3

A59

Cialdella

2001

U

U

U

U

N

Y

Y

High

C1.4

A63

Ernst

1990

U

U

U

U

Y

Y

N

High

C1.4

A56

Bignamini

1987

U

U

U

U

U

Y

N

High

C1.5

A84

Khuda-Bukhsh

2005

U

U

U

U

U

U

N

High

C1.6

A94

Lipman

1999

U

Y

Y

Y

N

N

Y

High

C2.1

A108

Rahlfs

1976

N

N

Y

Y

U

Y

Y

High

C2.1

A70

Friese

1997

U

U

Y

Y

N

N

Y

High

C2.2

A74

Gerhard (a)

1998

Y

U

Y

U

N

Y

N

High

C2.2

A74

Gerhard (b)

1998

Y

U

Y

U

N

Y

N

High

C2.2

A74

Gerhard (c)

1998

Y

U

Y

U

N

Y

N

High

C2.2

A89

Kotlus

2010

N

N

U

U

Y

Y

Y

High

C2.2

A50

Belon

2006

N

N

U

U

Y

Y

U

High

C2.3

A136

Wolf

2003

Y

U

U

U

Y

N

N

High

C2.3

A49

Beer

1999

U

U

U

U

Y

N

N

High

C2.4

A52

Bergmann (a)

2000

U

U

Y

U

U

N

N

High

C2.4

A52

Bergmann (b)

2000

U

U

Y

U

U

N

N

High

C2.4

A101

Oberbaum

2005

U

U

U

U

U

N

N

High

C2.5

A60

Clark

2000

U

U

U

U

N

N

N

High

C3.4

A85

Khuda-Bukhsh

2011

N

N

Y

Y

N

N

N

High

C5.0

A109

Rahlfs

1978

N

N

N d

N

N

Y

Y

High

C5.0

(b) Not included in meta-analysis

A80

Jacobs

2006

Y

Y

Y

Y

Y

N b

Y

High f

C1.0

A91

Labrecque

1992

Y

U

Y

Y

U

N b

Y

High e

C1.2

A274

Harrison

2013

Y

U

Y

Y

U

N b

U

High e

C1.3

A78

Hitzenberger

2005

U

U

Y

U

U

N b

Y

High e

C1.4

A277

Razlog

2012

U

U

Y

Y

U

N b

U

High e

C1.4

A117

Seeley

2006

U

U

U

U

Y

N b

U

High e

C1.5

A55

Berrebi

2001

U

U

U

U

U

N b

U

High e

C1.6

A76

Hart

1997

Y

Y

Y

Y

U

N

Y

High

C1.1

A116

Schmidt

2002

Y

Y

Y

Y

Y

N b

N

High

C2.0

A122

Stevinson

2003

Y

Y

Y

Y

Y

N b

N

High

C2.0

A278

Sencer

2012

U

Y

Y

Y

N

N b

Y

High

C2.1

A130

Weiser

1994

Y

U

Y

Y

N

N

Y

High

C2.1

A43

Aabel

2000

U

U

Y

Y

Y

N b

N

High

C2.2

A44

Aabel

2000

U

U

Y

Y

N

N b

U

High

C2.2

A42

Aabel

2001

U

U

U

Y

Y

N b

N

High

C2.3

A132

Wiesenauer

1989

U

U

Y

U

N

N

Y

High

C2.3

A53

Bernstein

2006

U

U

U

U

U

N b

N

High

C2.5

A69

Friese

2007

U

U

U

U

N

N

N

High

C3.4

A88

Kolia-Adam

2008

N

U

U

U

U

N

N

High

C3.4

A95

McCutcheon

1996

U

U

U

U

N

N b

N

High

C3.4

A51

Belon

2007

N

N

N d

N

N

N b

U

High

C6.1

Trials are arranged by risk of bias per category (a) and (b)

Y yes (low risk of bias), U unclear, N no (high risk of bias)

aReliable evidence

bData not extractable for meta-analysis

cUnless a published study protocol was available, completeness of reporting was judged solely on correspondence of Results with details in Methods section of paper

dA51 Belon and A109 Rahlfs, on initial full-text scanning, were deemed to have satisfactory participant/practitioner blinding – later refuted in detailed scrutiny

eExcept for domain V (data not extractable for meta-analysis), trial is otherwise uncertain risk of bias overall

fExcept for domain V (data not extractable for meta-analysis), trial is otherwise low risk of bias overall

There were three trials with reliable evidence (two ‘A’-rated, one ‘B1*’-rated), 23 with uncertain risk of bias (‘B’-rated), and 49 with high risk of bias (‘C’-rated). A summary risk-of-bias bar-graph is shown in Additional file 3.

Table 3a (54 trials included in meta-analysis): Two trials were ‘A’-rated (low risk of bias)—i.e. they fulfilled the criteria for all seven domains of assessment. Our criteria for reliable evidence were also satisfied for one ‘B1*’-rated trial. Table 3a therefore includes three trials that were classed reliable evidence: Plumbum metallicum for lead poisoning (A103: Padilha); the OTC complex Acthéane for menopausal syndrome (A272: Colau); the OTC complex Traumeel S for post-operative pain (A120: Singer). Each of the other 51 trials had uncertain or high risk of bias in important methodological aspects, and may be regarded as non-reliable evidence: 23 trials were classed as uncertain risk of bias; 28 were classed as high risk of bias.

Table 3b (21 trials excluded from meta-analysis): All of these 21 trials are ‘C’-rated (high risk of bias). Thirteen of the 21 were seriously flawed in more than one domain of assessment (i.e. rated ‘C2.0’ or worse). Seven of the remaining eight trials were ‘C’-rated solely because of data extraction issues: only one of those seven (A80: Jacobs) fulfilled ‘low risk-of-bias’ criteria for all other domains of assessment, and so would otherwise have been designated reliable evidence.

Meta-analysis

The pooled SMD (random-effects model) for all 54 trials was –0.33 (95% CI –0.44, –0.21; p < 0.001)—see Fig. 2.
Fig. 2
Fig. 2

Forest plot for 54 analysable RCTs of non-individualised homeopathy. Shows SMD (Treatment Effect, TE) and 95% confidence interval (CI). Pooled effects estimate shown for fixed-effect and random-effects model. W weighting

The original data extracted per trial (continuous or dichotomous), together with the correspondingly calculated SMD or OR, are illustrated in Additional files 4a and b.

Of the 31 trials with continuous data, 9 had an effect statistically significantly favouring homeopathy (i.e. SMD < 0, with p ≤ 0.05); no trials had an effect significantly favouring placebo. The pooled effect estimate was SMD = –0.36 (95% CI –0.52, –0.19; p < 0.001). Of the 23 trials with dichotomous data, 6 had an effect statistically significantly favouring homeopathy (i.e. OR > 1, with p ≤ 0.05); no trials had an effect significantly favouring placebo. The pooled effect estimate was OR = 1.67 (95% CI 1.25, 2.23; p < 0.001).

Heterogeneity and publication bias

The statistical heterogeneity among the studies was high (I 2 = 65%) – Fig. 2.

Evidence of publication bias, toward studies favouring homeopathy, was apparent from the funnel plot (Fig. 3a), which suggested a relative absence of studies favouring placebo. Egger’s test of asymmetry confirmed significant evidence of asymmetry in the funnel plot, p = 0.002. The estimated number of ‘missing’ studies was 11 (p for at least one ‘missing’ study was <0.001) – Fig. 3b. The effect estimate was attenuated when using the ‘trim-and-fill’ method to adjust for publication bias: after adjustment for ‘missing’ studies, the pooled effect estimate was –0.16 (95% CI –0.31, –0.02; p = 0.023); the statistical heterogeneity among the studies remained high (I 2 = 79%).
Fig. 3
Fig. 3

a Funnel plot for 54 RCTs of non-individualised homeopathy. Central vertical line is pooled effect estimate: SMD = –0.33. Heterogeneity statistic (I 2) = 65%. b Funnel plot for 54 RCTs of non-individualised homeopathy after ‘trim and fill’. Central vertical line is pooled effect estimate: SMD = –0.16. Heterogeneity statistic (I 2 ) = 79%

Risk of bias and reliable evidence

Figure 4 shows the SMD data for all 54 analysable trials, grouped by their risk of bias (high; uncertain; minimal or low [reliable evidence]).
Fig. 4
Fig. 4

Forest plots showing SMD (Treatment Effect, TE) and 95% confidence interval (CI) for RCTs of non-individualised homeopathy, with pooled SMD (random-effects model) for trials assessed as minimal or low risk of bias (reliable evidence; N = 3); uncertain risk of bias (non-reliable evidence; N = 23); high risk of bias (non-reliable evidence; N = 28)

  • High risk of bias/non-reliable evidence (‘C’-rated: N = 28): SMD = –0.38 (95% CI –0.50, –0.26; p < 0.001);

  • Uncertain risk of bias/non-reliable evidence (‘B’-rated: N = 23): SMD = –0.31 (95% CI –0.51, –0.11; p = 0.002);

  • Minimal or low risk of bias/reliable evidence (‘B1*’ plus ‘A’-rated: N = 3): SMD = –0.18 (95% CI –0.46, 0.09; p = 0.165).

From this risk-of-bias analysis, no significant difference was detected between the three pooled effect estimates (p = 0.417); meta-regression confirmed this finding (p = 0.617). There was thus no statistical evidence that effect estimates significantly differed depending on whether the body of evidence for a meta-analysis consisted of ‘low’, ‘uncertain’ or ‘high’ risk-of-bias studies.

Sensitivity analysis

Figure 5 shows the effect of cumulatively removing data by trials’ risk-of-bias rating. The pooled SMD showed a statistically significant effect in favour of homeopathy for all trials collectively, through to and including those rated ‘B3’; for the highest-rated trials collectively (‘B2’, ‘B1’ and ‘reliable evidence’), the pooled SMD still favoured homeopathy but was no longer statistically significant.
Fig. 5
Fig. 5

Sensitivity analysis, showing progressive effect on pooled SMD (treatment effect TE) of removing data by trials’ risk-of-bias rating

Sub-group analyses

The pooled SMD favoured homeopathy for all sub-groups, though it was statistically non-significant for two of the 18 (data imputed; combination medicine): Fig. 6a. A meta-regression was performed to test specifically for within-group differences for each sub-group. The results showed that there were no significant differences between studies that were and were not: included in previous meta-analyses (p = 0.447); pilot studies (p = 0.316); greater than the median sample (p = 0.298); potency ≥ 12C (p = 0.221); imputed for meta-analysis (p = 0.384); free from vested interest (p = 0.391); acute/chronic (p = 0.796); different types of homeopathy (p = 0.217).
Fig. 6
Fig. 6

Interactions between sub-groups for: a all N = 54 trials with analysable data; b N = 26 ‘A’- and ‘B’-rated trials

After removal of ‘C’-rated trials (Fig. 6b), the pooled SMD still favoured homeopathy for all sub-groups, but was statistically non-significant for 10 of the 18 (included in previous meta-analysis; pilot study; sample size > median; potency ≥12C; data imputed; free of vested interest; not free of vested interest; combination medicine; single medicine; chronic condition). There remained no significant differences between sub-groups—with the exception of the analysis for sample size > median (p = 0.028).

Analysis by clinical condition

Clinical conditions

Meta-analysis was possible for eight clinical conditions, each analysis comprising two to five trials (Fig. 7a). A statistically significant pooled SMD, favouring homeopathy, was observed for influenza (N = 2), irritable bowel syndrome (N = 2), and seasonal allergic rhinitis (N = 5). Each of the other five clinical conditions (allergic asthma, arsenic toxicity, infertility due to amenorrhoea, muscle soreness, post-operative pain) showed non-significant findings. Removal of ‘C’-rated trials negated the statistically significant effect for seasonal allergic rhinitis and left the non-significant effect for post-operative pain unchanged (Fig. 7b); no higher-rated trials were available for additional analysis of arsenic toxicity, infertility due to amenorrhoea or irritable bowel syndrome. There were no ‘C’-rated trials to remove for allergic asthma, influenza, or muscle soreness. Thus, influenza was the only clinical condition for which higher-rated trials indicated a statistically significant effect; neither of its contributing trials, however, comprised reliable evidence.
Fig. 7
Fig. 7

Meta-analysis by clinical condition for: a all N = 54 trials with analysable data; b N = 26 ‘A’- and ‘B’-rated trials. p values for pooled effect estimates: a Allergic asthma: p = 0.307; arsenic toxicity: p = 0.219; female infertility (amenorrhoea): p = 0.407; influenza: p = 0.025; irritable bowel syndrome: p = 0.009; muscle soreness: p = 0.762; post-operative pain: p = 0.143; seasonal allergic rhinitis: p = 0.001. b Allergic asthma: p = 0.307; influenza: p = 0.025; muscle soreness: p = 0.762; post-operative pain: p = 0.859; seasonal allergic rhinitis: p = 0.147

Categories of clinical condition

Meta-analysis was possible for 11 categories of clinical condition, each analysis comprising two to ten trials (Fig. 8a). A statistically significant pooled SMD, favouring homeopathy, was observed for five categories: allergy and asthma (N = 10); cardiovascular (N = 2); dermatology (N = 2); ear nose and throat (N = 3); gastroenterology (N = 2). None of the trials designated reliable evidence featured in any of these five categories. Each of the other six categories showed non-significant findings. Removal of ‘C’-rated trials limited each analysis to two to five trials (Fig. 8b): statistically significant effects were marginally retained for allergy and asthma (N = 5) and dermatology (N = 2), and more clearly retained for ear nose and throat (N = 2). No higher-rated trials were available for additional analysis in the cardiovascular and gastroenterology categories. After removal of ‘C’-rated trials, there was no change in the non-significance of the statistical findings for each of the other six categories.
Fig. 8
Fig. 8

Meta-analysis by category of clinical condition for: a all N = 54 trials with analysable data; b N = 26 ‘A’- and ‘B’-rated trials. p values for pooled effect estimates: a Allergy and asthma: p = 0.001; Cardiovascular: p = 0.046; Dermatology: p = 0.047; Ear, nose and throat: p = 0.014; Gastroenterology: p = 0.009; Mental disorder: p = 0.865; Musculoskeletal: p = 0.488; Obstetrics and gynaecology: p = 0.088; Respiratory infection: p = 0.092; Surgery and anaesthesiology: p = 0.448; Toxicology: p = 0.406. b Allergy and asthma: p = 0.041; Dermatology: p = 0.047; Ear, nose and throat: p < 0.001; Mental disorder: p = 0.165; Musculoskeletal: p = 0.762; Obstetrics and gynaecology: p = 0.486; Respiratory infection: p = 0.092; Surgery and anaesthesiology: p = 0.576; Toxicology: p = 0.896

Discussion

Seventy-two of the 75 eligible trials had uncertain or high risk of bias. Due to poor reporting or other deficiencies in 21 of the original papers, data extraction for our meta-analysis was possible from only 54 of the 75 trials. Trials with high and with uncertain risk of bias each featured similarly in our 54-trial analysis; the quality of the body of analysed evidence is therefore low.

As previously recognised [2, 7, 9], the pooling of data from diverse clinical conditions, outcome measures and end-points has obvious limitations: thus, a given pooled effect estimate here does not have a clear numerical meaning or relative clinical value, but provides a reasonable summary measure in evaluating the average effect of a medical intervention. Our null hypothesis that regards each trial of non-individualised homeopathy as testing the same intervention also has its limitations, for it makes the debatable assumption that each homeopathic medicine has similar lack of efficacy for the relevant symptoms of every clinical condition. Nevertheless, our separate focus on individualised [2] and non-individualised homeopathy marks a clear and appropriate step forward.

For our previous meta-analysis of RCTs (on individualised homeopathy [2]), the three most highly ranked trials had minimal risk of bias and were designated reliable evidence. In the current study, we have identified two trials with the highest-quality ranking (‘A’ = low risk of bias), plus one with minimal risk of bias (‘B1*’), which we have examined collectively as the reliable evidence of RCTs of non-individualised homeopathic treatment. Analysis of these three highest-quality trials showed a statistically non-significant pooled SMD of –0.18 (95% CI –0.46, 0.09) (equivalent to pooled OR = 1.39, using the standard conversion [14]). This effect estimate of –0.18 contrasts with that for all 54 analysable trials of –0.33 (equivalent to OR = 1.82): the latter represents a small and statistically significant treatment effect favouring homeopathy, akin to our pooled findings for the individualised trials [2]. We therefore reject the null hypothesis (non-individualised homeopathy is indistinguishable from placebo) on the basis of pooling all studies, but fail to reject the null hypothesis on the basis of the reliable evidence only. Our risk-of-bias analysis and the meta-regression, however, indicate that effect estimates do not significantly differ depending on whether the meta-analysis consists of ‘low’, ‘uncertain’ or ‘high’ risk-of-bias studies.

Lack of clear conclusion above might simply be due to there being too few high-quality trials. With only three studies that can be classified as reliable evidence, it is difficult to separate an effect of homeopathy from the effect of poor quality. The three studies comprising ‘reliable’ RCT evidence are clinically heterogeneous: Plumbum metallicum for lead poisoning ([23]; null effect); Acthéane for menopausal syndrome ([24]; significant treatment effect; evidence of vested interest); Traumeel S for post-operative pain ([25]; null effect). Since the completion of our defined literature search, we are aware of recently published and potentially eligible RCT papers, whose findings we have yet to explore [26–29]. The limit of detecting an effect of non-individualised homeopathy across all trials may be related to a medicine’s degree of dilution, since trials using potency ≥12C failed to show a statistically significant pooled effect that favoured homeopathy (see Fig. 6b).

In attempting to formulate a reasonable overarching conclusion, it is important also to highlight other findings from our quality-based analyses. For example, the sensitivity analysis that consecutively excluded the lowest-quality trials showed that studies with lower quality tended to report greater benefits of non-individualised homeopathic intervention than studies with higher quality. That RCTs with a higher risk of bias showed a greater benefit for the homeopathy group supports some previous—though not our own [2]—meta-analysis findings [4, 7, 10]. Our funnel plot finding of larger effect estimates (in favour of homeopathy) in trials with lower sample size is consistent with observations from RCTs in medicine more widely [30]. A further perspective, based on our trim-and-fill analysis, is that the true pooled effect estimate is likely to be smaller than initially appreciated: we found evidence of publication bias, with an estimated 11 ‘missing’ studies whose results would favour placebo, adjustment for which yielded an attenuated but still-significant pooled effect estimate of –0.16 for the 54 analysable trials. We are also aware that our analysis reflects per-protocol—not the potentially more robust (but less available) ITT—outcome data, which might have slightly magnified our pooled effect estimate; however, we have addressed the possible impact of incomplete data in rigorous risk-of-bias assessments, as recommended by Cochrane [31]. The sum of these comments supports a generalised conclusion that a non-individualised homeopathic medicine is indistinguishable from a placebo, but the quality of the evidence is low.

A small and erratic treatment effect in this context may be consistent with the notion that a pre-selected homeopathic medicine, aiming to treat the typical symptoms of a clinical condition, and given to all of the relevant trial participants, may match sub-optimally the ‘total symptom picture’ for an important number of them, leading potentially to diminished efficacy. The quality of the clinical intervention and the suitability of the main outcome measure are the key facets of a trial’s model validity, i.e. the extent to which a study reflects best clinical practice in that intervention [32]. Thus, to complete the quality evaluation of homeopathy trials, it is important to accommodate also the assessment of their model validity, emphasising in this case the three trials comprising reliable evidence in non-individualised homeopathic treatment.

We report separately our model validity assessments of these trials, evaluating consequently their overall quality based on a GRADE-like principle of ‘downgrading’ [14]: two trials [23, 25] rated here as reliable evidence were downgraded to ‘low quality’ overall due to the inadequacy of their model validity; the remaining trial with reliable evidence [24] was judged to have adequate model validity. The latter study [24] thus comprises the sole RCT that can be designated ‘high quality’ overall by our approach5, a stark finding that reveals further important aspects of the preponderantly low quality of the current body of evidence in non-individualised homeopathy.

Analysis by clinical condition, and following removal of ‘C’-rated studies, showed a statistically significant treatment effect in RCTs of non-individualised homeopathy for influenza, and in the categories allergy and asthma, dermatology, and ear nose and throat. None of these analyses included any reliable evidence, however. While these clinical categories do not provide compelling evidence for non-individualised homeopathic treatment, they may contain the most promising targets for future research.

Conclusions

There was a small, statistically significant, effect of non-individualised homeopathic treatment. However, the finding was not robust to sensitivity analysis based solely on the three trials that comprised reliable evidence: the effect size estimate collectively for those three trials was not statistically significant. There was significant evidence of publication bias in favour of homeopathy. Our meta-analysis of the current reliable evidence base therefore fails to reject the null hypothesis that the outcome of treatment using a non-individualised homeopathic medicine is not distinguishable from that using placebo. Nevertheless, the risk-of-bias analysis and the meta-regression, together with the large preponderance of low-quality evidence, challenge the inference that effect size estimates differ significantly depending on risk-of-bias rating. The assessment of a trial’s model validity should also be taken into account in an evaluation of overall study quality in homeopathy. Reliable evidence is lacking for all clinical conditions whose data have enabled separate meta-analysis. Higher-quality RCT research on specified homeopathic medicines is required to enable more decisive interpretation regarding efficacy for given clinical symptoms or conditions. Future trialists need to minimise their studies’ risk of bias in all domains, and to improve the clarity of their reporting. Such research might wisely focus on trial design in which only patients that match the relevant ‘symptom picture’ or match the indications of the selected homeopathic product are those eligible to participate: large trials are therefore indicated.

Footnotes
1

In practice, data were not derivable from the three relevant trials with continuous data: due to the original authors’ use of either medians or ‘change’ data only.

 
2

This nomenclature is not intended to be definitive, but a basis for more refined analysis at a later date.

 
3
 
4

Additional file 2 represents an update of the flowchart included in the original study protocol [3].

 
5

Mathie RT, Van Wassenhoven M, Rutten ALB, Klein-Laansma CT, Eizayaga J, Pla i Castellsagué A, Jong MC, Manchanda RK, Dantas F, Oberbaum M, Frye J, Roniger H, Baumgartner S, van Haselen R, Nicolai T, Fisher P. Model validity of randomised placebo-controlled trials of non-individualised homeopathic treatment. Submitted for publication.

 

Abbreviations

CI: 

Confidence interval

GRADE : 

Grades of Recommendation, Assessment, Development and Evaluation

ICF: 

International Classification of Functioning

ITT: 

Intention to treat

OR: 

Odds ratio

OTC: 

Over-the-counter

PRISMA : 

Preferred Reporting Items for Systematic Reviews and Meta-Analyses

RCT: 

Randomised controlled trial

SD: 

Standard deviation

SMD: 

Standardised mean difference

WHO: 

World Health Organization

Declarations

Acknowledgements

Professor Ian Ford, Robertson Centre for Biostatistics, University of Glasgow, helped develop the statistical protocol for the study. We thank Daniela Hacke, Karl und Veronica Carstens-Stiftung, Essen, Germany, for assistance with the literature search and retrieval of relevant full-text articles.

Funding

The systematic review programme is supported by a grant from the Manchester Homeopathic Clinic.

Availability of data and materials

All key data generated or analysed during this study are included in this published article [and its supplementary information files]. The original datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

RTM devised and led the study, developed the study protocol and contributed to all facets of the work except the statistical analysis. NR conducted the statistical analyses, contributed to data interpretation and edited the manuscript. LAL helped to develop the study protocol, co-assessed trials for risk of bias, contributed to data interpretation and edited the manuscript. JC helped to develop the study protocol, co-assessed trials for risk of bias, contributed to data interpretation and edited the manuscript. SM co-assessed trials for risk of bias, contributed to data interpretation and edited the manuscript. JRTD helped to develop the study protocol, co-assessed trials for risk of bias, contributed to data interpretation and edited the manuscript. C-MM contributed to statistical analysis, data interpretation and editing the manuscript. AM contributed to data interpretation and edited the manuscript. All authors have applied the normal high standards of scientific method in the conduct of the work and of complete and transparent reporting in the write-up of the paper; they have all read and approved the final manuscript.

Competing interests

Authors RTM, JC and SM are (or were) associated with a homeopathy charity whose principal aim is to clarify and extend an evidence base in homeopathy. RTM holds an independent research consultancy contract with the Deutsche Homöopathie-Union, Karlsruhe, Germany. RTM, JC and SM have no other relationships or activities that could appear to have influenced the submitted work. The University of Glasgow (authors NR, C-MM and AMcC) was supported by a grant from the British Homeopathic Association (now administered by the Homeopathy Research Institute, which holds the grant following its transfer from the BHA) during the conduct of the study; neither NR, C-MM nor AMcC has any other relationships or activities that could appear to have influenced the submitted work. Author JRTD had no support from any organisation for the submitted work; in the last 3 years, and for activities outside the submitted study, he received personal fees, royalties or out-of-pocket expenses for advisory work, invitational lectures, use of rating scales, published book chapters, or committee membership; he receives royalties from Springer Publishing Company for his book, A Century of Homeopaths: Their Influence on Medicine and Health. JTRD has no other relationships or activities that could appear to have influenced the submitted study.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Homeopathy Research Institute, London, UK
(2)
Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
(3)
Department of Biomedical Engineering, University of Strathclyde, Glasgow, UK
(4)
Karl und Veronica Carstens-Stiftung, Essen, Germany
(5)
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA

References

  1. European Committee for Homeopathy. Homeopathy Definition. http://homeopathyeurope.org/practice/. Accessed 27 Oct 2016.
  2. Mathie RT, Lloyd SM, Legg LA, Clausen J, Moss S, Davidson JRT, Ford I. Randomised, placebo-controlled, trials of individualised homeopathic treatment: systematic review and meta-analysis. Syst Rev. 2014;3:142.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Mathie RT, Legg LA, Clausen J, Davidson JRT, Lloyd SM, Ford I. Systematic review and meta-analysis of randomised, placebo-controlled, trials of non-individualised homeopathic treatment: study protocol. Version 1.0; 30 October 2014. http://www.britishhomeopathic.org/wp-content/uploads/2014/10/SR+MA-Protocol-Non-indiv-Hom-30-10-14-2-column++.pdf. Accessed 5 July 2016.
  4. Kleijnen J, Knipschild P, ter Riet G. Clinical trials of homoeopathy. BMJ. 1991;302:316–23.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Boissel JP, Cucherat M, Haugh M, Gauthier E. Critical literature review on the effectiveness of homoeopathy: overview of data from homoeopathic medicine trials. In: Homoeopathic Medicine Research Group Report. Commission of the European Communities, Directorate-General XII – Science, Research and Development, Directorate E – RTD Actions: Life Sciences and Technologies – Medical Research. Brussels: Commission of the European Communities; 1996.Google Scholar
  6. Cucherat M, Haugh MC, Gooch M, Boissel JP. Evidence of clinical efficacy of homeopathy – A meta-analysis of clinical trials. Eur J Clin Pharmacol. 2000;56:27–33.View ArticlePubMedGoogle Scholar
  7. Linde K, Clausius N, Ramirez G, Melchart D, Eitel F, Hedges LV, Jonas WB. Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo-controlled trials. Lancet. 1997;350:834–43.View ArticlePubMedGoogle Scholar
  8. Linde K, Scholz M, Ramirez G, Clausius N, Melchart D, Jonas WB. Impact of study quality on outcome in placebo-controlled trials of homeopathy. J Clin Epidemiol. 1999;52:631–6.View ArticlePubMedGoogle Scholar
  9. Shang A, Huwiler-Muntener K, Nartey L, Juntherapiesi P, Dorig S, Sterne JA, Pewsner D, Egger M. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet. 2005;366:726–32.View ArticlePubMedGoogle Scholar
  10. Linde K, Melchart D. Randomized controlled trials of individualized homeopathy: a state-of-the-art review. J Altern Complement Med. 1998;4:371–88.View ArticlePubMedGoogle Scholar
  11. Mathie RT, Hacke D, Clausen J, Nicolai T, Riley DS, Fisher P. Randomised controlled trials of homeopathy in humans: characterising the research journal literature for systematic review. Homeopathy. 2013;102:3–24.View ArticlePubMedGoogle Scholar
  12. World Health Organization. Towards a Common Language for Functioning, Disability and Health. ICF: The International Classification of Functioning, Disability and Health. Geneva: World Health Organization; 2002.Google Scholar
  13. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions; Version 5.1.0. The Cochrane Collaboration; 2011.Google Scholar
  14. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions; Version 5.1.0. The Cochrane Collaboration; 2011.Google Scholar
  15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.View ArticlePubMedGoogle Scholar
  16. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions; Version 5.1.0. The Cochrane Collaboration; 2011.Google Scholar
  17. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Duval SJ, Tweedie RL. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.View ArticlePubMedGoogle Scholar
  19. Duval SJ, Tweedie RL. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95:89–98.Google Scholar
  20. Schwarzer G. meta: general package for meta-analysis. 2015. http://CRAN.R-project.org/package=meta.Google Scholar
  21. Bellavite P, Marzotto M, Olioso D, Moratti E, Conforti A. High-dilution effects revisited. 1. Physicochemical aspects. Homeopathy. 2014;103:4–21.View ArticlePubMedGoogle Scholar
  22. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions; Version 5.1.0. The Cochrane Collaboration; 2011.Google Scholar
  23. Padilha RQ, Riera R, Atallah ÁN. Homeopathic Plumbum metallicum for lead poisoning: a randomized clinical trial. Homeopathy. 2011;100:116–21.View ArticlePubMedGoogle Scholar
  24. Colau JC, Vincent S, Marijnen P, Allaert FA. Efficacy of a non-hormonal treatment, BRN-01, on menopausal hot flashes: a multicenter, randomized, double-blind, placebo-controlled trial. Drugs R D. 2012;12:107–19.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Singer SR, Amit-Kohn M, Weiss S, Rosenblum J, Maoz G, Samuels N, Lukasiewicz E, Freedman L, Paltiel O, Itzchaki M, Niska M, Oberbaum M. Traumeel S for pain relief following hallux valgus surgery: a randomized controlled trial. BMC Clin Pharmacol. 2010;10:9.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Misael PCE, de Guadalupe TMBM, del CSGM P, Carlos RLJ. Effect of Cynara scolymus (artichoke) in homeopathic doses on body mass index in obese and overweight patients. Biomed Pharmacol J. 2014;7:525–33.View ArticleGoogle Scholar
  27. Dossett ML, Mu L, Davis RB, Bell IR, Lembo AJ, Kaptchuk TJ, Yeh GY. Patient-provider interactions affect symptoms in gastroesophageal reflux disease: a pilot randomized, double-blind, placebo-controlled trial. PLoS One. 2015;10:e0136855.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Chaiet SR, Marcus BC. Perioperative Arnica montana for reduction of ecchymosis in rhinoplasty surgery. Ann Plast Surg. 2016;76:477–82.View ArticlePubMedGoogle Scholar
  29. Zafar S, Najam Y, Arif Z, Hafeez A. A randomized controlled trial comparing Pentazocine and Chamomilla recutita for labor pain relief. Homeopathy. 2016;105:66–70.View ArticlePubMedGoogle Scholar
  30. Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. JAMA. 2012;308:1676–84.View ArticlePubMedGoogle Scholar
  31. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions; Version 5.1.0. The Cochrane Collaboration; 2011.Google Scholar
  32. Mathie RT, Roniger H, Van Wassenhoven M, Frye J, Jacobs J, Oberbaum M, Bordet M-F, Nayak C, Chaufferin G, Ives JA, Dantas F, Fisher P. Method for appraising model validity of randomised controlled trials of homeopathic treatment: multi-rater concordance study. BMC Med Res Methodol. 2012;12:49.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement

Systematic Reviews

ISSN: 2046-4053